Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Want to see KYTX full AI Analyst Report?
Top Page
Kyverna Therapeutics, Inc.
(NASDAQ:KYTX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$9.50
▼(-4.33% Downside)
Action:ReiteratedDate:04/24/26
The score is held back primarily by weak financial performance—no recent revenue, widening losses, and accelerating cash burn—despite a low-debt balance sheet. Offsetting factors include strong positive clinical-data corporate updates and moderately constructive technical momentum, while valuation is constrained by negative earnings and no indicated dividend support.
Positive Factors
Registrational clinical success for miv-cel
Durable, statistically significant Phase 2/registrational results across KYSA-6 and KYSA-8 materially strengthen Kyverna's regulatory and commercial pathway for miv-cel. Single-dose durability and immunotherapy-free outcomes support a differentiated, potentially first-in-class position in neuroimmunology.
Negative Factors
No recent revenue and widening operating losses
Absence of recurring revenue and sharply widening net losses indicate dependence on capital markets to fund operations. Persistent negative profit trends undermine self-sustainability and increase the likelihood of dilutive financings or strategic deal-making to support commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Registrational clinical success for miv-cel
Durable, statistically significant Phase 2/registrational results across KYSA-6 and KYSA-8 materially strengthen Kyverna's regulatory and commercial pathway for miv-cel. Single-dose durability and immunotherapy-free outcomes support a differentiated, potentially first-in-class position in neuroimmunology.
Read all positive factors
Kyverna Therapeutics, Inc. (KYTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$541.75M
Dividend YieldN/A
Average Volume (3M)658.87K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue GrowthN/A
EPS Growth-21.22%
CountryUS
Employees112
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,439,890
10 Day Avg. Volume664,385
30 Day Avg. Volume658,872
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-165.02
Enterprise Value/Ebitda-1.84
Forecast
1Y Price Target
$29.00Price Target Upside192.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.05
Revenue Forecast (FY)N/A
Kyverna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate fo...
How the Company Makes Money
null...
Kyverna Therapeutics, Inc. Earnings Call Summary
Earnings Call Date:Nov 13, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The earnings call revealed significant advancements in Chimera's immunology pipeline, particularly with the initiation of KT61 and advancement of KT474. However, the deprioritization of the oncology program and extended timelines for KT474 indicate strategic shifts that could pose challenges. The financial stability and focus on promising immunology assets contribute to an overall positive outlook.Positive Updates
Phase One Study of KT61 Initiated
Chimera Therapeutics has started the phase one study of KT61, a first-in-class oral STAT6 degrader. This marks the first STAT6 medicine to enter clinical development, with potential to transform treatment paradigms for diseases like atopic dermatitis, asthma, and COPD.
Negative Updates
Oncology Program Deprioritized
Chimera has decided to advance only KT333 and KT253 beyond phase one with a partner, reallocating resources towards the immunology pipeline.
Read all updates
Q3-2024 Updates
Positive
Negative
Phase One Study of KT61 Initiated
Chimera Therapeutics has started the phase one study of KT61, a first-in-class oral STAT6 degrader. This marks the first STAT6 medicine to enter clinical development, with potential to transform treatment paradigms for diseases like atopic dermatitis, asthma, and COPD.
Read all positive updates
Company Guidance
During the Chimera Therapeutics Q3 2024 earnings call, significant guidance was provided, highlighting several key metrics and strategic directions. The company has initiated a Phase 1 study of KT61, an oral STAT6 degrader, with expectations to complete the Healthy Volunteer Study in the first half of 2025. The program aims to address diseases with TH2 inflammation, affecting over 150 million patients across the US, Europe, and Japan. Additionally, Chimera has advanced its KT474 program, transitioning it to expanded Phase 2B studies, supported by partner Sanofi, and is preparing KT295, a new lead candidate in their TIC2 program, for Phase 1 trials in 2025. Financially, Chimera raised approximately $600 million in 2024, boasting a cash runway into mid-2027, and reported $3.7 million in revenue for the quarter, attributed to their Sanofi collaboration. The company is strategically reallocating resources to prioritize their growing immunology pipeline, with plans to share further guidance on clinical developments next year.Kyverna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 7.03M | 5.66M |
| Gross Profit | -1.80M | -2.13M | -1.71M | 7.03M | 5.66M |
| EBITDA | -167.38M | -125.20M | -58.47M | -27.78M | -25.76M |
| Net Income | -161.31M | -127.48M | -60.37M | -28.89M | -26.35M |
Balance Sheet | |||||
| Total Assets | 293.83M | 304.64M | 75.19M | 66.92M | 85.49M |
| Cash, Cash Equivalents and Short-Term Investments | 279.25M | 285.98M | 57.54M | 51.32M | 76.07M |
| Total Debt | 29.03M | 8.24M | 9.08M | 10.56M | 5.55M |
| Total Liabilities | 61.55M | 38.06M | 26.02M | 20.25M | 131.74M |
| Stockholders Equity | 232.28M | 266.59M | 49.18M | 46.68M | -46.25M |
Cash Flow | |||||
| Free Cash Flow | -153.72M | -116.45M | -53.03M | -36.88M | -23.44M |
| Operating Cash Flow | -153.71M | -114.25M | -52.41M | -36.11M | -22.16M |
| Investing Cash Flow | 40.02M | -160.90M | -8.79M | -14.10M | -1.29M |
| Financing Cash Flow | 141.17M | 337.11M | 58.12M | 11.88M | 72.52M |
Kyverna Therapeutics, Inc. Technical Analysis
Positive
9.93
Price Trends
8.41
Positive
8.40
Positive
6.74
Positive
Market Momentum
0.35
Negative
63.81
Neutral
79.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYTX, the sentiment is Positive. The current price of 9.93 is above the 20-day moving average (MA) of 8.74, above the 50-day MA of 8.41, and above the 200-day MA of 6.74, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 63.81 is Neutral, neither overbought nor oversold. The STOCH value of 79.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYTX.
Kyverna Therapeutics, Inc. Risk Analysis
Kyverna Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Kyverna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kyverna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $541.75M | -2.58 | -81.41% | ― | ― | -21.22% | |
57 Neutral | $439.79M | -1.84 | -46.34% | ― | ― | 14.33% | |
55 Neutral | $490.42M | -2.96 | -39.83% | ― | -71.42% | -248.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $228.99M | -3.23 | -90.51% | ― | -17.87% | 14.42% | |
50 Neutral | $188.50M | -10.73 | 304.91% | ― | 12.60% | 58.23% | |
49 Neutral | $370.31M | -6.10 | -300.94% | ― | ― | ― |
* Healthcare Sector Average
KYTX
Kyverna Therapeutics, Inc.
8.95
6.81
318.22%
CDXS
Codexis
2.52
0.22
9.57%
HRTX
Heron Therapeutics
1.00
-1.27
-55.99%
SLN
Silence Therapeutics
7.84
4.33
123.36%
AVIR
Atea Pharmaceuticals
5.52
2.65
92.33%
TRDA
Entrada Therapeutics Inc
12.81
3.85
42.97%
Kyverna Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
Positive
Apr 22, 2026
On April 20, 2026, Kyverna Therapeutics reported positive longer-term Phase 2 follow-up data from the KYSA-6 Phase 2/3 trial of its CAR T candidate miv-cel in generalized myasthenia gravis, showing deepening responses, durable benefit out to 52 we...
Business Operations and StrategyProduct-Related Announcements
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
Positive
Apr 22, 2026
On April 21, 2026, Kyverna reported positive primary analysis results from its registrational Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome, with data presented as a late-breaking oral session at the American Academy of Neurology meetin...
Business Operations and StrategyProduct-Related Announcements
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
Positive
Apr 20, 2026
On April 20, 2026, Kyverna Therapeutics reported positive longer-term Phase 2 data from its KYSA-6 registrational trial of miv-cel in patients with generalized myasthenia gravis, showing deep, durable clinical responses through one year after a si...
Executive/Board Changes
Kyverna Therapeutics Strengthens Board With New Director Appointments
Positive
Feb 24, 2026
On February 24, 2026, Kyverna Therapeutics appointed biopharma veteran Andrew Miller, Ph.D., as a Class III director, adding him to its Science and Technology and Audit committees and granting him cash retainers and equity awards aligned with its ...
Business Operations and StrategyExecutive/Board Changes
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing
Positive
Feb 3, 2026
On January 29, 2026, Kyverna Therapeutics announced that Chief Technology Officer Karen Walker would retire effective February 9, 2026, with the company emphasizing that her departure was not due to any disagreement over its operations, policies o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.